EMA Authorised: Evotaz (cobicistat;atazanavir) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Evotaz, a fixed-dose combination of cobicistat and atazanavir, for the treatment of Human immunodeficiency virus infect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• EVOTAZ (atazanavir and cobicistat)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 02/05/2025